In this automated system for assaying guanidino compounds, the compounds are resolved on an ion-exchange (Dowex 50) column, then reacted with phenanthrenequinone in alkaline solution. This mixture is then acidified and the resulting fluorescence is measured (Xex, 305 nm; X, 395 nm).Iapplied thesystem to the analysis of urine from control i'ats and rats given L-canavanine, L-canavaninosuccinic acid, L-guanidinosuccinic acid, L-arginine, or urea, intraperitoneally. The recorder tracings are compared with those obtained for urine from healthy and uremic humans. After urea administration some guanidinosuccinate is excreted, along with substantial quantities of another substance that elutes just before guanidinosuccinate and so may be mistaken for it.
substantial quantities of another substance that elutes just before guanidinosuccinate and so may be mistaken for it.
Urine from uremic humans also shows this unidentified peak, but not urine from untreated rats or healthy humans. LCanavanine gives rise, mainly, to guanidine and homosenne, apparently by reduction. Similarly, canavaninosuccinate is reduced to homoserine and guanidinosuccinate. Arginine givesrise to small quantities of guanidinosuccinate. Guanidinosuccinate is excretedmainlyunchanged.When the guanidinosuccinate concentration is increased, excretion of guanidinoacetic acid is suppressed.
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L-arginine . homoserine metabolism of guanidino compounds . continuous-f/ow analysis
In an earlier publication it was proposed that urea is probably a precursor of guanidinosuccinic acid and that this pathway is involved in the reutilization of nitrogen from urea (1). The argument for this was based on several observations, including the fact that guanidinosuccinate concentrations are above normal in the blood and urine of uremic patients (2) (3) (4) (5) (6) (7) and that, when arginine concentrations in blood are increased owing to a genetic arginase deficiency, such persons do not excrete excessive amounts of guanidinosuccinic acid (8, 9). This latter observation casts doubt on the probability thatguanidinosuccinate is made by transamidination from arginine to aspartic acid (10) . This concept has been tested recently (11) by incubating isolated liver cells with various concentrations of urea and measuring the guanidinosuccinate formed in the incubation medium. In theseexperiments, which involved "high-performance"
liquid chromatography and fluorimetry, a peak was observed at the location for guanidinosuccinate, the height ofwhichwas related directly to theurea concentration (11). Ammonia did not have the same effect. In these studies, the guanidino compounds were fractionated on a column of Dowex-50 and the effluent was heated with phenanthrenequinone in alkaline solution in an automated system (12).
Reaction of phenanthrenequinone with guanidino compounds in alkaline solution yields a broad excitation 14-fold, depending on which compound is being tested (14). In addition, the emission band shifts away from the erniesion band of phenanthrenequinone, which also autofluoresces in alkaline solution, thus decreasing the blank response. I therefore devised an automated system in which the effluent from the column could be heated with alkaline phenanthrenequinone, and then acidified before fluorimetry. The column was operated at low pressures, with a peristaltic pump. A fraction collector was used to collect fractions corresponding to peaks of fluorescence, so their constituents could be positively identified.
All ofthe reactions of theschemeproposed earlier for the existence of a "guanidine cycle" were shown to take placein vitro, withhuman and rat liver and kidney tissue (15) (16) (17) (18) (19) (20) . A major objection raisedto these studies was that these reactions had not been demonstrated in the intact animal. In addition, a reportappeared suggesting that a major pathway for canavanine metabolism was by way of the formation of hydroxyguanidine.
This suggestion was based on the isolation of hydroxyguanidine from the urine of rats injected with D,L-canavamne
(21).
To explore the significance of the observations summarized above, I applied the automated guanidino analyzer to the analysis of urine from untreated rats and rats injected intraperitoneally with urea, canavamne, canavaninosuccinate, guanidinosuccinate, or arginine. The object was to ascertain the fate of the compounds injected into the intact animal, the better to understand guanidine metabolism.
In addition, the guarndinocompounds in urine from three uremic patients were examined and comparedwith those in urine from healthy men. and serves as the injection port. Pump the buffers through the other leg to the column by means of a peristaltic pump at a rate of 1.5 mLlmin. Divide the effluent from the column so that 1 mL/min is assayed and 0.5 mL/min is guided to a Gilson microfraction collector, collecting 1-mL fractions at 2-mm intervals (Figure 1 ).
Materials and Methods

Reagents
Move the sample and reagents by means of a peristaltic pump, whose rate of rotation can be adjusted continuously (Rohe Sci. Co., Santa Ana, CA 92711). Adjust the pump rate to 1 mLlmin through the yellow-blue coded tube, which is flow rated at 1.4 mL/min (0.06-in, bore). Now set up the manifold as shown in Figure 1 . With this assembly, mix the eluate with 0.2 mmo)JL anthraquinone solution, 1 molIL NaOH solution, and air. Heat for 3 mm at 68#{176}C in the reservoir with the circulating water used for the column, then cool with tap water. After de.-bubbling the stream, pass it through the fluorimeter, set at 305 nm (excitation) and 395 nm (emission). Adjust these wavelengths for maximum response with a processed guanidino compound passing through the fluorimeter.
Adjust the recorder so that the paper moves at 0.1 inch/mm.
Regenerate the column by successively pumping water, 3 mollL HC1, water, 3 moIfL NaOH, water, and pH 3.3 buffer, each for 20 mm.
Instrument Operation
Pump the pH 3.3 buffer through the system (Figure 1 The rat urine extractwas dilutedso that 80 nmol of creatininewas lrected onto the column was 6.5. After centrifugation, an aliquot of the supernate was sterilized by passage through a 0.22-pin ifiter.
I injected, intraperitoneally, 1 mL (0.5 mmol) of these solutions into each of the rats in the different sets. They were given food and water ad lib. The urine from each set was collected and filtered. I added 1 g of solid trichioroacelic acid to 9 mL of urine from each set, mixed well, and allowed it to stand for 10 mm, then centrifuged. The supernate was assayed forcreatinine, and a sample was injected into the chromatograph as described above. In some cases, with urine from uremic humans, the relative density and creatinine concentration of the urine were low. In these cases,a 40-mL aliquot of urine was lyophilized, reconstituted to 10 mL with water, and processed like theurine from control specimens.
Colorimetric Reactions
The various colorimetric reactions ( Tables 1 and 2) were carried out in accordance with minor modifications of procedures already described (2,10,18,22).
For Cut out the homoserine lactone-stained paper for the standard, urine, recovery, and a blank made by spraying the paper with the ninhydrin spray and heating as for the unknown.
Elute the stains with 5 mL of dimethyl sulfoxide. Decant the emerald-colored solution and measure its absorbance at 500 nm. Note that for the urine the location of the homoserine lactone is determined from the recovery, since the lactone moves somewhat more slowly when dissolved in urine.
Thin-LayerChromatography and Electrophoresis
Use Eastman orMerck 20 x 20cm plastic plates on which a layer of cellulose has been deposited. Deposit 5 pL of the samples, 2.5 cm apart, and allow toair dry. Dip theplates into the developing solution (contained in the thin-layer chromatography chamber)
made by mixing 120 mL of butanol, 30 mL ofglacial aceticacid, and 50 mL of water. Allow to develop until the solvent has moved 15 cm. Dry the sheet inairand spray with the reagents listed in Table 1 . 
Results and Discussion
The urine from theratsinjected with urea showed a peak at the location for guanidinosuccinate, which was identified as such by the Sakaguchi and diacetyl reactions and its location on electrophoresis ( Figure   3A ). This also showed the characteristic wider tracing obtained with low concentrations of guanidinosuccinate.
Thus,the high guanidinosuccinate concentrations observed in uremic patients' urine and blood could be attributed to higher urea concentrations ( Figures 4A, SA, and SB) .
Unreported, however, was the sharp unidentified peak labeledY in Figure 3A , which was located close to that of guanidinosuccinate.
This peak was not ascribable to urea, hydroxyurea, creatine, or guanidinoglutarate. 5A , and SB) but could not be demonstrated in the urine from the control rats or humans whose serum urea concentrations were within the normal range, even when greater amounts of urine were addedtothe column (Figures 29, 3B, and 4A) . Analysis of the urine from rats injected with i.-canavanine confirms the observations made with both human and rat liver extract: canavamne is readily reduced to guanidine and homoserine (19). That this is a major pathway is apparent from Figure 6A , where the guanidine is obviously the major guanidino component ofthe urine. In addition to guarndine, substantial amounts of guanidinoacetate and arginine were found ( Figure GA, Table 3 ). i-
Canavanine transamidinates
to neutral (glycine) and basic (orrnthine) amino acids (15, 24, 25) . This explains the increased amounts of these components in the urine when i..-canavanine is injected (Table 3) . Along with the products mentioned above, a small amount of guanidinosuccinate was formed. This probably originated from urea formed by the action of arginase on i-canavanine
(26).
Homosenne was also shown to be present in the urine in Figure GA by the two peaks obtained with the amino acid analyzer (27). When assayed semi-quantitatively by electrophoresis, after conversion to the lactone, the urine was shown to contain 15 mol of homoserine per milliliter or 180 molI24 h, a figure that should be compared with the figure of 238 molJ24 h obtained for the guanidines (Table 3) . When urine from the rats given i.-canavanine was concentrated 10-fold, and 25 .iL was subjected to electrophoresis, no hydroxyguanidine could be detected. Figure 7A shows that hydroxyguanidine appears just before arginine on the tracing.
It appears as a negative peak, because it destroys the reagent. Figure GA shows no negative peak at this location. In urine, the guanidine derivatives move some- Table 1 . Thus methylguanidine appears at the location for hydroxyguanidine.
When D,L-canavanlne was injected, hydroxyguanidine appearedin the urine (21). It is claimed that the hydroxyguanidine arises from 1)-amino-acid oxidase (EC 1.4.3.3 ) action on canavanine, and subsequent separation of hydroxyguanidine from the oxidized molecule (28). 1)-Amino-acid oxidase does not act on i.-canavanine.
After L-.canavaninosuccinate injection, the main fraction found in the urine was guanidinosuccinate (Figure 69 ). This supports the concept that the main pathway of ircanavaninosuccinate metabolism is by reduction to homoserine and guanidinosuccinate, as has been demonstrated in vitro with human and rat liver (21). Figure Table 3 ).
The urine of
Canavaninosuccinate,
like arginosuccinate, has a tendency to form an anhydride when chromatographed at acid pH.
This is shown in Figure 7B . Multifunctional compounds such as guanidinosuccinate, argininosuccinate, and canavaninosuccinate will exhibit wider bands because,at pH 3.3-4.9, they exist in several ionic forms. The cyclized form, being a single ion, willshow a sharp peak ( Figure 7B ). In Bothshowbroad bandsfor the acid form and sharp peaksafter cyclization as a spike just behind creatinine. This was demonstrated to be distinct from 'guanidinobutyric acid, which appears just ahead of this location, and canavanine, which appears just behind this site.
Canavamnosuccinate can also dissociate to form fumarate and canavanine (16). Thus, those substances that increased in the urine when canavanine was administered were also increased when canavaninosuccinate was injected: guanidine, arginine, and guanidinosuccinate (Table 3) . Figure   6B , when canavaninosuccinate was administered.
Of interest is the appearance of the peak labeled Y in
There is no assurance that this is the same substance that appeared when urea was administered.
If itproves to be so, then it would tie canavaninosuccinate and canavanine to urea metabolism. In earlier publications, itwas claimed that guanidinosuccinate was an end product of metabolism(18). In those studies about three-fourths ofthe guanidinosuccinate administered to rats was recovered intheurine within thefirst (Figure 89 ), where guanidinoacetate and guanidinosuccinate concentrations are increased. This also confirms similar observations made by others (32). Arginine excretion is increased, but only a small fraction of that injected is accounted for in the urine. As yet unexplained is the fact that guanidine excretion is doubled (21, 32) .
Here I have established that urinary guanidinosuccinate is increased when the animal's urea pool is increased, either exogenously or endogenously (Tables 3 and 4) . Of significance is the appearance of an unidentified compound, in substantial concentrations, in urine from either uremic patients or rats to which urea was administered. This compound appears as a peak close to that for guanidinosuccinate, for which it may be mistaken, and it needs to be identified.
The major mechanism of metabolism for canavanine and canavaninosuccinate in vivo is shown to be by reduction to form homoserine and guanidine or guanidinosuccinate, respectively. That guanidinosuccinate is an end product of metabolism, and is excreted in the urine, is confirmed. Guanidinosuccinate suppresses the concentration of guanidinoacetate in the urine. Thus these studies confirm our earlier reports on the metabolism of these guanidino compounds as deduced from studies with tissue extracts.
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